SCHEMBL12093378

SCHEMBL12093378

CCCCOC[C@H]1CN(S(=O)(=O)c2cccs2)CCN1

nearest known ligand 0.48

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PKM P14618 3/20 0.44
MEN1 O00255 4/20 0.42
KMT2A Q03164 4/20 0.42
POLB P06746 2/20 0.42
ALDH1A1 P00352 2/20 0.42
MAPK1 P28482 2/20 0.42
TSHR P16473 2/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
HTT P42858 1/20 0.41
GAA P10253 2/20 0.41
MAPT P10636 2/20 0.41
KDM4E B2RXH2 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12079068 0.82 ALDH1A1 (0.51) PKMMEN1KMT2APOLBALDH1A1
SCHEMBL17508 0.82 ALDH1A1 (0.51) PKMMEN1KMT2APOLBALDH1A1
SCHEMBL18930 0.76 GCK (0.43) PKMMEN1KMT2AALDH1A1TSHR
SCHEMBL17416 0.76 ALDH1A1 (0.62) PKMMEN1KMT2APOLBALDH1A1
SCHEMBL18037 0.76 PKM (0.59) PKMMEN1KMT2APOLBALDH1A1
SCHEMBL20111 0.76 PKM (0.59) PKMMEN1KMT2APOLBALDH1A1
SCHEMBL17885 0.75 GCKR (0.56) MAPT
SCHEMBL17646 0.75 GCKR (0.56) MAPT
Hydrochloric Acid SCHEMBL16219 0.75 PKM (0.58) PKMMEN1KMT2APOLBALDH1A1
Hydrochloric Acid SCHEMBL16217 0.75 PKM (0.58) PKMMEN1KMT2APOLBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8431563-B2 Compounds that interact with glucokinase regulatory protein for the treatment of diabetes AMGEN INC. (US) 2013-04-30 US disclosed
US-20120225854-A1 COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES AMGEN INC. (US) 2012-09-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120225854-A1 COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES GCKR, GCK, SLC5A2 PKM 197/4885MEN1 4072/4885KMT2A 3843/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.